The Legal Landscape of Peptides: What 'Research Only' Really Means

What the "research use only" label does and doesn't do

Almost every peptide vendor prints a version of the same line: "For research use only. Not for human consumption." It's there because most of the peptides lifters buy are not approved drugs in the US. BPC-157 and TB-500 have no FDA approval for any use, and neither do the growth hormone secretagogues CJC-1295 and ipamorelin. Without an approval, nobody can lawfully market them for people to use, so they're sold as laboratory reagents instead.

The label protects sellers less than many buyers assume. Under federal drug law (the FD&C Act), a product's legal status depends on its intended use, and FDA judges that from the whole sales page, not the disclaimer alone. On August 24, 2026, FDA sent warning letters to several online peptide sellers. Each letter said the products were "intended to be drugs for human use" despite their research-use statements.

FDA pointed to two kinds of evidence. One was health-related product copy, even when it was phrased as "studied for" or "investigated for." The other was the sale of bacteriostatic water, which FDA said provides "the means to prepare an injectable drug for human administration." One letter also cited the seller's peptide guide and dosing calculator.

Semaglutide and tesamorelin, both named in those letters, are the active ingredients of FDA-approved prescription medicines. That didn't change the outcome. A research-labeled vial of an approved molecule is a separate product with no approval of its own, and FDA called each one an unapproved new drug.

Peptides, steroids and SARMs under US law

Anabolic steroids are Schedule III controlled substances. Possessing one without a valid prescription is a federal crime under 21 U.S.C. 844. For a first offense the penalty is up to 1 year in prison and a minimum fine of $1,000, which makes simple possession a misdemeanor rather than a felony. Felony exposure comes mainly with distribution: up to 10 years for a first Schedule III offense under 21 U.S.C. 841. State laws add their own penalties.

SARMs are not controlled substances. As of October 2026 there is no federal scheduling and no pending bill. The last attempt, the SARMs Control Act of 2019 (S. 2895), never got a vote and died at the end of that Congress. FDA calls SARMs unapproved drugs and says they "cannot be legally marketed in the U.S. as a dietary supplement or drug," including when they're sold "for research use only."

Most research peptides land in the same place as SARMs. They're unapproved drugs under the FD&C Act and sit outside the Controlled Substances Act entirely. The FD&C Act's core prohibitions target introducing drugs into interstate commerce, so enforcement falls mainly on sellers. Most of it takes the form of warning letters. Those letters threaten seizure and injunction if the violations continue.

For more on how steroid and SARM law works on its own terms, see our US legal landscape analysis.

Could a peptide be scheduled?

Older guides warn that the Federal Analogue Act could reach peptides. That's unlikely. The Act only covers substances "substantially similar" to a Schedule I or II drug in chemical structure or in effects on the central nervous system. Steroids are Schedule III. Healing peptides and GH secretagogues don't resemble Schedule I or II drugs either. Controlling a peptide would most likely take a formal scheduling proceeding by DEA or HHS, and we found none for any peptide on this page.

Compounding: the prescription route and where it stands

Outside a clinical trial, the main lawful route to an unapproved peptide for human use in the US would be a compounding pharmacy filling a prescription. Under section 503A of the FD&C Act, pharmacies can compound only from eligible bulk ingredients, and for these peptides the test is whether the substance appears on FDA's 503A bulks list (21 CFR 216.23). As of September 2026 that list held six substances, none of them a peptide.

While nominations wait for review, FDA sorts them into interim categories. In September 2023 it placed roughly 19 peptides in Category 2 (substances that may present significant safety risks), which in practice stopped pharmacies from compounding them. LumaLex Law, a firm that advises compounders, says this pushed demand toward gray and black markets. 2026 brought a run of changes, none of them final:

• April 2026: after the original nominators withdrew, FDA announced on April 15 that 12 peptides, including BPC-157 and TB-500, would leave Category 2. Law firm Orrick noted that removal lifts the "significant safety risk" designation but doesn't authorize compounding.
• July 23-24, 2026: FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven of those peptides. FDA staff recommended against listing all seven. According to LumaLex's account, the committee voted 8-6-1 to recommend adding both BPC-157 and TB-500, also backed KPV, MOTS-c, Semax and epitalon, and voted against DSIP. FDA hasn't published official tallies.
• Before the end of February 2027: a second PCAC meeting is planned for GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF.

The committee's vote is advice. Adding a substance to the 503A list takes notice-and-comment rulemaking, and as of October 2026 FDA hasn't published a proposed rule for any of these peptides, so none can yet be compounded under 503A. Even a future listing would only allow pharmacy compounding against a prescription. It wouldn't make research-labeled vials legal to sell for human use.

CJC-1295 and ipamorelin weren't part of the 2026 reviews. As of October 2026, FDA's Category 2 page lists both as "nominated but withdrawn." For CJC-1295 it cites serious adverse events including increased heart rate and a systemic vasodilatory reaction; for ipamorelin it cites a published study reporting serious adverse events, including death, after intravenous use. Ipamorelin acetate also remains in Category 2 for 503B outsourcing facilities, and neither peptide is on the 503A bulks list.

Importing and buying

Many research peptides ship from overseas. FDA's personal importation guidance says that "in most circumstances" it is illegal for individuals to import unapproved drugs for personal use. The reasons FDA gives for refusing a personal shipment include a product on an import alert and a product that appears to present a serious health risk.

For buyers, the most direct federal exposure is a package detained or refused at the border. The bigger practical issue is quality: no regulator checks what's in a research vial, so its contents rest on the vendor's own testing claims.

Rules outside the US differ; our country-by-country guide covers them.

Tested athletes: legal to buy doesn't mean allowed

Anti-doping rules run separately from US law. WADA's 2026 Prohibited List, in force since January 1, 2026, bans the common performance peptides both in and out of competition:

• BPC-157 is named in S0, non-approved substances.
• TB-500 falls under S2.3, which lists "Thymosin-ß4 and its derivatives e.g. TB-500".
• GHRH analogues such as CJC-1295 and tesamorelin, plus GH secretagogues such as ipamorelin and GHRP-6, sit in S2.2.4.
• IGF-1 analogues (including IGF-1 LR3) and mechano growth factors are in S2.3.
• GH fragments such as AOD-9604 are in S2.2.3.

The 2027 list takes effect on January 1, 2027. According to USADA, it names "peptides" in general as an example of S0 substances, so an unnamed research peptide with no approval anywhere is still covered. Athletes are strictly liable for whatever is in their system. Semaglutide and tirzepatide are the notable exceptions: they stay in WADA's 2027 monitoring program and are not prohibited.

Our article on peptides and anti-doping rules covers testing and sanctions in more detail.

What legal status doesn't tell you about the science

The research-only status doesn't say whether a peptide works or is safe. It reflects that no company has taken these compounds through approval. For BPC-157 the evidence gap is wide. A 2025 systematic review of its musculoskeletal research included 36 studies, and 35 of them were preclinical. Rodent findings on tendon and ligament repair are fairly consistent, but human data come from a handful of small uncontrolled reports, and no controlled human trial has published results as of October 2026. That is also why the site rates BPC-157's evidence as emerging rather than strong.

What to watch next

• Whether FDA proposes a rule for the six peptides the PCAC backed in July 2026.
• The second PCAC meeting, planned before the end of February 2027.
• Further FDA warning letters to research-use sellers. The August 2026 round focused on GLP-1 drugs and other approved molecules sold as research vials.
• The 2027 WADA list, in force from January 1, 2027.